Shares of Johnson & Johnson (NYSE:JNJ) have been given a consensus rating of “Buy” by the nine brokerages that are currently covering the company, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $190.38.
JNJ has been the subject of a number of research analyst reports. Credit Suisse Group set a $193.00 price target on Johnson & Johnson and gave the stock a “buy” rating in a report on Monday, June 7th. Morgan Stanley began coverage on Johnson & Johnson in a report on Friday, May 28th. They set an “overweight” rating and a $187.00 price target for the company.
Hedge funds have recently modified their holdings of the stock. OLD Mission Capital LLC bought a new stake in shares of Johnson & Johnson in the 3rd quarter valued at about $362,000. Sage Mountain Advisors LLC bought a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $525,000. Ironwood Wealth Management LLC. grew its position in shares of Johnson & Johnson by 1,559.2% in the 4th quarter. Ironwood Wealth Management LLC. now owns 7,400 shares of the company’s stock valued at $1,165,000 after buying an additional 6,954 shares during the last quarter. Mattern Capital Management LLC grew its position in shares of Johnson & Johnson by 3.5% in the 4th quarter. Mattern Capital Management LLC now owns 30,032 shares of the company’s stock valued at $4,726,000 after buying an additional 1,014 shares during the last quarter. Finally, United Bank grew its position in shares of Johnson & Johnson by 46.4% in the 4th quarter. United Bank now owns 9,863 shares of the company’s stock valued at $1,552,000 after buying an additional 3,127 shares during the last quarter. Institutional investors and hedge funds own 66.60% of the company’s stock.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 20th. The company reported $2.48 EPS for the quarter, topping analysts’ consensus estimates of $2.29 by $0.19. Johnson & Johnson had a return on equity of 34.62% and a net margin of 17.95%. The company had revenue of $23.31 billion during the quarter, compared to analysts’ expectations of $22.54 billion. During the same quarter in the previous year, the firm earned $1.67 EPS. Johnson & Johnson’s revenue was up 27.1% on a year-over-year basis. As a group, sell-side analysts anticipate that Johnson & Johnson will post 9.51 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 7th. Investors of record on Tuesday, August 24th will be given a dividend of $1.06 per share. The ex-dividend date of this dividend is Monday, August 23rd. This represents a $4.24 dividend on an annualized basis and a yield of 2.49%. Johnson & Johnson’s dividend payout ratio is currently 52.80%.
Johnson & Johnson Company Profile
Johnson & Johnson researches and develops, manufactures, and sells a range of products in the health care field worldwide. It operates through three segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Article: Hedge Funds Explained
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.